Syntekabio to Promote Customized Partnering by AI Drug Platform at 'BIO USA 2024'

Artificial intelligence (AI) new drug development specialist company Syntekabio announced on the 29th that it will set up a promotional booth at the ‘Bio International Convention 2024 (BioUSA)’ to promote its AI new drug platform.

BioUSA is the world's largest bio-industry conference where pharmaceutical and bio companies and industry stakeholders from around the globe gather to discuss global business. It is held annually in major cities located in the U.S. bio clusters. This year, it will take place in San Diego, California, USA, from the 3rd to the 6th of next month (local time).

Participating for the second consecutive year, Syntekabio plans to install a standalone booth of 56㎡ (17 pyeong) within the bioprocess zone. It will promote the newly launched STB LaunchPad service, the representative AI new drug platform ‘DeepMatcher®’, the neoantigen prediction platform ‘NEO-ARS®’, and the antibody drug prediction and discovery platform ‘Ab-ARS™’.

The company plans to highlight its differentiated competitiveness, including its AI new drug platform capabilities that can collaborate up to synthetic drugs and biopharmaceutical development, DeepMatcher, and an automated AI new drug candidate discovery system based on its own supercomputing center and cloud infrastructure. It will focus on attracting global customers and securing contracts, conducting customized partnering according to client needs, and exploring business cooperation opportunities.

Additionally, the booth’s wall will emphasize the STB LaunchPad service. STB LaunchPad is an AI new drug development service that utilizes a database (DB) of various stages of active substance data derived in advance for over 130 target proteins related to more than 15 diseases, including inflammation, autoimmune diseases, cancer, brain diseases, and skin diseases. Since new drug development starts from the active substance stage, it can accelerate the development speed. It also guarantees the discovery of active substances for desired targets.

Jung Jong-sun, CEO of Syntekabio, stated, “Our goal is to penetrate the global market and secure contracts through BioUSA,” adding, “We will do our utmost to achieve rapid results, led by STB LaunchPad based on the automated AI new drug candidate discovery system this year.”